Hong Kong Personal Products Stock News

As global markets navigate a complex landscape of economic resilience and inflationary pressures, Asian equities have shown mixed performance amid these shifting dynamics. For investors interested in smaller or newer companies, penny stocks—despite the term's somewhat outdated nature—remain a compelling area for potential growth. These stocks, often characterized by their affordability and growth potential when supported by robust financials, can offer intriguing opportunities; this article...

XJ International Holdings Co., Ltd. ( HKG:1765 ) posted some decent earnings, but shareholders didn't react strongly...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Dynagreen...

Readers hoping to buy Beijing Tong Ren Tang Chinese Medicine Company Limited ( HKG:3613 ) for its dividend will need to...

It looks like Water Oasis Group Limited ( HKG:1161 ) is about to go ex-dividend in the next three days. The ex-dividend...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Pokfulam...

As Asian markets navigate a landscape of mixed economic signals and geopolitical tensions, investors are increasingly focused on identifying opportunities that may be undervalued amidst the broader uncertainty. In this context, finding stocks that are priced below their estimated value can offer potential advantages, especially when considering factors such as resilience in specific sectors or strong fundamentals that could withstand regional volatility.

Amidst a backdrop of mixed global market performance, Asian small-cap stocks have captured investor attention as potential opportunities for growth and diversification. With the Russell 2000 Index showing notable year-to-date gains, investors are increasingly looking towards smaller companies that demonstrate resilience and innovation in challenging economic environments. Identifying promising small caps often involves focusing on firms with strong fundamentals, innovative business models,...

Industrial and Commercial Bank of China (SEHK:1398) has just completed a RMB 60,000 million Tier 2 capital notes issuance in the National Interbank Bond Market, a financing step aimed at strengthening its tier 2 capital position. See our latest analysis for Industrial and Commercial Bank of China. The HK$6.83 share price has a 1-day share price return of 1.64% and a 7-day share price return of 2.86%. The 1-year total shareholder return of 26.07% and 5-year total shareholder return of 104.62%...

China Resources Beverage (Holdings) (SEHK:2460) has drawn investor attention after shareholders approved both a final dividend and a special dividend for 2025 at the company’s latest annual general meeting. See our latest analysis for China Resources Beverage (Holdings). Despite the dividend approvals, the stock’s recent momentum has been weak, with a 30 day share price return of down 6.24% and a year to date share price return of down 19.94%, while the 1 year total shareholder return is down...

Bank of Qingdao (SEHK:3866) has put shareholder returns and capital structure in focus after its 2025 AGM, approving a cash dividend and confirming the full early redemption of its RMB 2b tier two capital bonds. See our latest analysis for Bank of Qingdao. Recent price action has been mixed, with a 1-day share price return of 0.69% at HK$4.35 following the AGM, set against a 30-day share price decline of 9.38%. However, the year to date share price return of 13.87% and a 3-year total...

Governance changes and recent financial recovery take center stage Kingdee International Software Group (SEHK:268) has drawn fresh attention after shareholders approved new amended and restated Articles of Association, together with the company’s recent shift from a net loss to net income in 2025. See our latest analysis for Kingdee International Software Group. Despite the recent governance changes and return to profitability, the share price has been under pressure, with the 1-year total...

Those following along with FWD Group Holdings Limited ( HKG:1828 ) will no doubt be intrigued by the recent purchase of...

Potential CStone Pharmaceuticals ( HKG:2616 ) shareholders may wish to note that the CEO, President of R&D and...

Investors who take an interest in China Wantian Holdings Limited ( HKG:1854 ) should definitely note that the Executive...

Over the past year, insiders sold CN¥5.6m worth of Fujing Holdings Co., Limited ( HKG:2497 ) stock at an average price...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Tongguan Gold...

Insiders who acquired HK$2.48m worth of Anchorstone Holdings Limited's ( HKG:1592 ) stock at an average price of...

Kowloon Development Company Limited ( HKG:34 ) stock is about to trade ex-dividend in 3 days. The ex-dividend date...

Recent share price move puts Shenzhen Creality 3D Technology in focus A sharp one day move has put Shenzhen Creality 3D Technology (SEHK:3388) on investors’ radar, with the stock falling about 9% in the latest session and roughly 8% year to date. With a market value of about HK$9.8b and reported revenue of CN¥3,127.04m against a net loss of CN¥182.561m, the company sits at an interesting point for investors assessing growth potential versus current profitability. See our latest analysis for...

It looks like Fountain Set (Holdings) Limited ( HKG:420 ) is about to go ex-dividend in the next 3 days. The...

Recent share performance and company snapshot WuXi Biologics (Cayman) (SEHK:2269) has seen mixed share performance recently, with the stock edging up about 1% over the past day but declining around 10% over the past 3 months. The company runs an end to end biologics contract research, development, and manufacturing business, serving clients across North America, Europe, the People’s Republic of China, and other regions. It reported revenue of CN¥21,790.018 million and net income of...

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500. The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s...

Everest Medicines Stock Moves After Recent Performance Metrics Everest Medicines (SEHK:1952) has drawn fresh attention as investors review recent share performance and financial metrics, with the stock down 1% over the past day and 4.6% over the past week. See our latest analysis for Everest Medicines. That 1 day and 7 day share price weakness comes on top of a 30 day share price return of down 14.8% and a year to date decline of 24.1%. The 3 year total shareholder return of about 1.7x the...